866-997-4948(US-Canada Toll Free)

Respiratory Syncytial Virus (RSV) Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Published By :

Transparency Market Research

Published Date : Apr 2018

Category :

Therapeutic Area

No. of Pages : 176 Pages

Global Respiratory Syncytial Virus (RSV) Therapeutics Market: Overview

Respiratory syncytial virus infection is highly contagious. It is reported to be the most common cause of pneumonia and bronchiolitis in children as well as adults. According to the Center for Disease and Prevention, around 25-40 of every 100 children exposed to RSV infection for the first time develop signs of bronchiolitis or pneumonia. No approved drugs have been available in the market to treat RSV infection till date, and only prophylaxis drugs have been used. Therefore, several biopharmaceutical companies are investing in research and development in order to develop new drugs and vaccine to treat or prevent the RSV infection.

The global respiratory syncytial virus (RSV) therapeutics market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drugs type, dosage form, distribution channel, and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. Additionally, the section comprises competitive matrix and company profiles with business overview in order to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global respiratory syncytial virus (RSV) therapeutics market.

Global Respiratory Syncytial Virus (RSV) Therapeutics Market: Key Segments

Based on drugs type, the global respiratory syncytial virus (RSV) therapeutics market can be segmented into palivizumab, ribavirin, and others. The drug type segments have been analyzed based on type of drug uses to treat RSV infection in the different region. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. According to dosage form, the global respiratory syncytial virus (RSV) therapeutics market can be classified into oral, injectable, and others. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.

Global Respiratory Syncytial Virus (RSV) Therapeutics Market: Regional Outlook

In terms of geography, the global respiratory syncytial virus (RSV) therapeutics market has been categorized into five major regions and the key countries in the respective region: North America (the U.S., Canada), Europe (the U.K., Germany, France, Italy, Spain and Rest of Europe), Asia Pacific (China, Japan, India, Australia & New Zealand and Rest of Asia Pacific), Latin America (Brazil, Mexico and Rest of Latin America) and Middle East and Africa (GCC Countries, South Africa, Israel, and Rest of MEA). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the respiratory syncytial virus (RSV) therapeutics market are include F. Hoffmann-La Roche Ltd., AstraZeneca plc, Merck & Co., Inc., AbbVie, Inc., Valeant Pharmaceuticals International, Inc, GlaxoSmithKline plc., ReViral Ltd., Gilead Sciences, Inc., and Teva Pharmaceutical Industries Ltd.

The global respiratory syncytial virus (RSV) therapeutics market has been segmented as follows:

Respiratory Syncytial Virus (RSV) Therapeutics Market, by Drugs Type

  • Palivizumab
  • Ribavirin
  • Others

Respiratory Syncytial Virus (RSV) Therapeutics Market, by Dosage Form

  • Oral
  • Injectable
  • Others

Respiratory Syncytial Virus (RSV) Therapeutics Market, by Distribution Channel

  • Drug Stores and Retail Pharmacies
  • Hospital Pharmacies
  • Others

Respiratory Syncytial Virus (RSV) Therapeutics Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa

Table of Content

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary : Global Respiratory Syncytial Virus (RSV) Therapeutics Market

Chapter 4. Market Overview
4.1. Introduction
4.1.1. Product Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Pipeline Analysis – Respiratory Syncytial Virus (RSV) Therapeutics Market
4.4. Epidemiology Assessment - Respiratory Syncytial Virus (RSV) Therapeutics Market
4.5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, 2015-2025
4.5.1. Market Revenue Projection (US$ Mn)
4.5.2. Market Outlook
4.6. Key Trends

Chapter 5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, by Drugs Type
5.1. Key Findings / Developments
5.2. Introduction & Definition
5.3. Market Value Forecast, by Drugs Type, 2016–2025
5.3.1. Palivizumab
5.3.2. Ribavirin
5.3.3. Others
5.4. Market Attractiveness, by Drugs Type

Chapter 6. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, by Selection Technique
6.1. Key Findings / Developments
6.2. Introduction & Definition
6.3. Market Value and Volume Forecast, by Dosage Form, 2016–2025
6.3.1. Oral
6.3.2. Injectable
6.3.3. Others
6.4. Market Attractiveness, by Dosage Form

Chapter 7. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, by Distribution Channel
7.1. Key Findings / Developments
7.2. Introduction & Definition
7.3. Market Value and Volume Forecast, by Distribution Channel, 2017–2025
7.3.1. Drug Stores & Retail Pharmacies
7.3.2. Hospital Pharmacies
7.3.3. Others
7.4. Market Attractiveness, by Distribution Channel

Chapter 8. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, by Geography/Region
8.1. Geographical Representation
8.2. Market Value and Volume Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region

Chapter 9. North America Respiratory Syncytial Virus (RSV) Therapeutics Analysis and Forecast
9.1. Market Value Forecast, by Country , 2016–2025
9.1.1. U.S.
9.1.2. Canada
9.2. Market Value Forecast, by Drugs Type, 2016–2025
9.3. Market Value Forecast, by Dosage Form, 2016–2025
9.4. Market Value Forecast, by Distribution Channel, 2016-2025
9.5. Market Attractiveness Analysis
9.5.1. By Country
9.5.2. By Drugs Type
9.5.3. By Dosage Form
9.5.4. By Distribution Channel
9.6. Key Trends

Chapter 10. Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
10.1. Market Value Forecast, by Country , 2017–2025
10.1.1. Germany
10.1.2. France
10.1.3. U.K.
10.1.4. Spain
10.1.5. Italy
10.1.6. Rest of Europe
10.2. Market Value Forecast, by Drugs Type, 2016–2025
10.3. Market Value Forecast, by Dosage Form, 2016–2025
10.4. Market Value Forecast, by Distribution Channel, 2016-2025
10.5. Market Attractiveness Analysis
10.5.1. By Country
10.5.2. By Drugs Type
10.5.3. By Dosage Form
10.5.4. By Distribution Channel
10.6. Key Trends

Chapter 11. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
11.1. Market Value Forecast, by Country , 2017–2025
11.1.1. China
11.1.2. Japan
11.1.3. India
11.1.4. Australia & New Zealand
11.1.5. Rest of APAC
11.2. Market Value Forecast, by Drugs Type, 2016–2025
11.3. Market Value Forecast, by Dosage Form, 2016–2025
11.4. Market Value Forecast, by Distribution Channel, 2016-2025
11.5. Market Attractiveness Analysis
11.5.1. By Country
11.5.2. By Drugs Type
11.5.3. By Dosage Form
11.5.4. By Distribution Channel
11.6. Key Trends

Chapter 12. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
12.1. Market Value Forecast, by Country, 2017–2025
12.1.1. Brazil
12.1.2. Mexico
12.1.3. Rest of LATAM
12.2. Market Value Forecast, by Drugs Type, 2016–2025
12.3. Market Value Forecast, by Dosage Form, 2016–2025
12.4. Market Value Forecast, by Distribution Channel, 2016-2025
12.5. Market Attractiveness Analysis
12.5.1. By Country
12.5.2. By Drugs Type
12.5.3. By Dosage Form
12.5.4. By Distribution Channel
12.6. Key Trends

Chapter 13. Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
13.1. Market Value Forecast, by Country, 2017–2025
13.1.1. GCC Countries
13.1.2. South Africa
13.1.3. Israel
13.1.4. Rest of Middle East & Africa
13.2. Market Value Forecast, by Drugs Type, 2016–2025
13.3. Market Value Forecast, by Dosage Form, 2016–2025
13.4. Market Value Forecast, by Distribution Channel, 2016-2025
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Drugs Type
13.5.3. By Dosage Form
13.5.4. By Distribution Channel
13.6. Key Trends

Chapter 14. Competition Landscape
14.1. Competition Matrix
14.1.1. Merck & Co., Inc.
14.1.2. F. Hoffmann-La Roche Ltd.
14.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.2.1. F. Hoffmann-La Roche Ltd. (HQ, Business Segments, Employee Strength)
14.2.1.1. Company Details
14.2.1.2. Company Description
14.2.1.3. Business Overview
14.2.1.4. SWOT Analysis
14.2.1.5. Financial Analysis
14.2.1.6. Strategic Overview
14.2.2. AstraZeneca plc. (HQ, Business Segments, Employee Strength)
14.2.2.1. Company Details
14.2.2.2. Company Description
14.2.2.3. Business Overview
14.2.2.4. SWOT Analysis
14.2.2.5. Strategic Overview
14.2.3. Merck 7 Co., Inc. (HQ, Business Segments, Employee Strength)
14.2.3.1. Company Details
14.2.3.2. Company Description
14.2.3.3. Business Overview
14.2.3.4. SWOT Analysis
14.2.3.5. Strategic Overview
14.2.4. AbbVie, Inc. (HQ, Business Segments, Employee Strength)
14.2.4.1. Company Details
14.2.4.2. Company Description
14.2.4.3. Business Overview
14.2.4.4. SWOT Analysis
14.2.4.5. Strategic Overview
14.2.5. Valeant Pharmaceuticals International, Inc. (HQ, Business Segments, Employee Strength)
14.2.5.1. Company Details
14.2.5.2. Company Description
14.2.5.3. Business Overview
14.2.5.4. SWOT Analysis
14.2.5.5. Financial Analysis
14.2.5.6. Strategic Overview
14.2.6. GlaxoSmithKline plc. (HQ, Business Segments, Employee Strength)
14.2.6.1. Company Details
14.2.6.2. Company Description
14.2.6.3. Business Overview
14.2.6.4. SWOT Analysis
14.2.6.5. Financial Analysis
14.2.6.6. Strategic Overview
14.2.7. ReViral Ltd. (HQ, Business Segments, Employee Strength)
14.2.7.1. Company Details
14.2.7.2. Company Description
14.2.7.3. Business Overview
14.2.7.4. SWOT Analysis
14.2.7.5. Financial Analysis
14.2.7.6. Strategic Overview
14.2.8. Gilead Sciences, Inc. (HQ, Business Segments, Employee Strength)
14.2.8.1. Company Details
14.2.8.2. Company Description
14.2.8.3. Business Overview
14.2.8.4. SWOT Analysis
14.2.8.5. Financial Analysis
14.2.8.6. Strategic Overview
14.2.9. MEDIVIR AB (HQ, Business Segments, Employee Strength)
14.2.9.1. Company Details
14.2.9.2. Company Description
14.2.9.3. Business Overview
14.2.9.4. SWOT Analysis
14.2.9.5. Strategic Overview
14.2.10. Teva Pharmaceuticals Industries Ltd. (HQ, Business Segments, Employee Strength)
14.2.10.1. Company Details
14.2.10.2. Company Description
14.2.10.3. Business Overview
14.2.10.4. SWOT Analysis
14.2.10.5. Strategic Overview

List of Table

Table 01: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type/Vaccine, 2015–2025
Table 02: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form 2015–2025
Table 03: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel 2015–2025
Table 04: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 05: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 06: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type, 2015–2025
Table 07: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2015–2025
Table 08: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 09: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country/ Sub-Region, 2015–2025
Table 10: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type, 2015–2025
Table 11: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2015–2025
Table 12: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 13: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 14: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type, 2015–2025
Table 15: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2015–2025
Table 16: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 17: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 18: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type, 2015–2025
Table 19: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2015–2025
Table 20: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 21: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub Region, 2015–2025
Table 22: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type, 2015–2025
Table 23: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2015–2025
Table 24: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025a

List of Chart

Figure 01: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
Figure 02: Global Respiratory Syncytial virus (RSV) Therapeutics Market Value Share, by Type of Drugs/Vaccine (2016)
Figure 03: Global Respiratory Syncytial virus (RSV) Therapeutics Market Value Share, by Dosage Form (2016)
Figure 04: Global Respiratory Syncytial virus (RSV) Therapeutics Market Value Share, by Distribution Channel (2016)
Figure 05: Global Respiratory Syncytial Virus (RSV) Therapeutics Market, by Drug Type/Vaccine, 2016 and 2025
Figure 06: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Drug Type/Vaccine: Palivizumab, 2015–2025
Figure 07: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Drug Type/Vaccine: Ribavirin, 2015–2025
Figure 08: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Drug Type/Vaccine: Others, 2015–2025
Figure 09: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drug Type/Vaccine, 2017–2025
Figure 10: Global Respiratory Syncytial Virus (RSV) Therapeutics Market, by Dosage Form, 2016 and 2025
Figure 11: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Dosage Form: Oral, 2015–2025
Figure 12: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Dosage Form: Injectable, 2015–2025
Figure 13: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Dosage Form: Others, 2015–2025
Figure 14: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Dosage Form, 2017–2025
Figure 15: Global Respiratory Syncytial Virus (RSV) Therapeutics Market, by Distribution Channel, 2016 and 2025
Figure 16: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Distribution Channel: Drug Stores and Retail Pharmacies, 2015–2025
Figure 17: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Distribution Channel: Hospital Pharmacies 2015–2025
Figure 18: Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Distribution Channel: Others, 2015–2025
Figure 19: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Distribution Channel, 2017–2025
Figure 20: Global Respiratory syncytial virus (RSV) Therapeutics Market Value Share, by Region, 2016 and 2025
Figure 21: Respiratory Syncytial virus (RSV) Therapeutics Market Attractiveness Analysis, by Region, 2016–2024
Figure 22: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 23: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Country, 2017 and 2025
Figure 24: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Country, 2017–2025
Figure 25: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2016 and 2025
Figure 26: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drug Type, 2017–2025
Figure 27: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, Dosage Form, 2016 and 2025
Figure 28: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, Dosage Form, 2017–2025
Figure 29: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2016 and 2025
Figure 30: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 31: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 32: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Country/Sub-Region, 2016 and 2025
Figure 33: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Country/Sub-Region, 2017–2025
Figure 34: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2016 and 2025
Figure 35: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drug Type, 2017–2025
Figure 36: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, Dosage Form, 2016 and 2025
Figure 37: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, Dosage Form, 2017–2025
Figure 38: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2016 and 2025
Figure 39: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 40: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 41: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Country, 2016 and 2025
Figure 42: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Country, 2017–2025
Figure 43: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2016 and 2025
Figure 44: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drug Type, 2017–2025
Figure 45: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, Dosage Form, 2016 and 2025
Figure 46: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, Dosage Form, 2017–2025
Figure 47: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2016 and 2025
Figure 48: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 49: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 50: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Country, 2016 and 2025
Figure 51: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Country, 2017–2025
Figure 52: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2016 and 2025
Figure 53: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drug Type, 2017–2025
Figure 54: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, Dosage Form, 2016 and 2025
Figure 55: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, Dosage Form, 2017–2025
Figure 56: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2016 and 2025
Figure 57: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 58: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 59: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Country/Sub Region, 2016 and 2025
Figure 60: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Country/Sub Region, 2017–2025
Figure 61: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2016 and 2025
Figure 62: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drugs Type, 2017–2025
Figure 63: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, Dosage Form, 2016 and 2025
Figure 64: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, Dosage Form, 2017–2025
Figure 65: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2016 and 2025
Figure 66: Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 67: Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 68: R&D Intensity (US$ Bn), 2015–2016
Figure 69: Breakdown of Net Sales of Diabetes Care Business Area, by Region 2016
Figure 70: Breakdown of Net Sales, by Diagnostic Division, 2016
Figure 71: Breakdown of Net Sales, by Region, 2017 (%)
Figure 72: R&D Intensity and Sales & Marketing Intensity – Company Level, (US$ Bn), 2016–2017
Figure 73: Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 74: Breakdown of Net Sales, (by Business Segment), 2017
Figure 75: Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 76: R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 77: Breakdown of Net Sales, by Region (Company Level), 2016
Figure 78: Breakdown of Net Sales, (Overall Company Level), 2016
Figure 79:  Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 80: Breakdown of Net Sales, by Region, 2016

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *